Apex Biotechnology (Taiwan) Insiders
| 1733 Stock | TWD 30.90 0.10 0.32% |
Apex Biotechnology employs about 17 people. The company is managed by 6 executives with a total tenure of roughly 40 years, averaging almost 6.0 years of service per executive, having 2.83 employees per reported executive. Recap of Apex Biotechnology's management performance can provide insight into the venture performance.
| Ben Shen Insider VP Sales |
| Ying Zhu Insider F Head |
Apex |
Apex Biotechnology Management Team Effectiveness
The company has return on total asset (ROA) of 0.0434 % which means that it generated a profit of $0.0434 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1279 %, meaning that it generated $0.1279 on every $100 dollars invested by stockholders. Apex Biotechnology's management efficiency ratios could be used to measure how well Apex Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities.Apex Biotechnology Workforce Comparison
Apex Biotechnology Corp is rated second in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 110. Apex Biotechnology retains roughly 17.0 in number of employees claiming about 15% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.1 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.08 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.08. Apex Biotechnology Notable Stakeholders
An Apex Biotechnology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Apex Biotechnology often face trade-offs trying to please all of them. Apex Biotechnology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Apex Biotechnology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Ben Shen | VP Sales | Profile | |
| Ying Zhu | F Head | Profile | |
| Meng Yang | VP GM | Profile | |
| Thomas Shen | CEO Chairman | Profile | |
| James Chu | Chief Officer | Profile | |
| Chun Wu | VP Spokesman | Profile |
About Apex Biotechnology Management Performance
The success or failure of an entity such as Apex Biotechnology Corp often depends on how effective the management is. Apex Biotechnology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Apex management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Apex management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Apex Biotechnology Corp. engages in the research, development, manufacture, and sale of medical devices by using biosensor technology worldwide. Apex Biotechnology Corp. was founded in 1997 and is headquartered in Hsinchu, Taiwan. APEX BIOTECHNOLOGY operates under Biotechnology classification in Taiwan and is traded on Taiwan Stock Exchange.
Please note, the imprecision that can be found in Apex Biotechnology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Apex Biotechnology Corp. Check Apex Biotechnology's Beneish M Score to see the likelihood of Apex Biotechnology's management manipulating its earnings.
Apex Biotechnology Workforce Analysis
Traditionally, organizations such as Apex Biotechnology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Apex Biotechnology within its industry.Apex Biotechnology Manpower Efficiency
Return on Apex Biotechnology Manpower
| Revenue Per Employee | 125.4M | |
| Revenue Per Executive | 355.3M | |
| Net Income Per Employee | 11.9M | |
| Net Income Per Executive | 33.7M | |
| Working Capital Per Employee | 65.9M | |
| Working Capital Per Executive | 186.8M |
Additional Tools for Apex Stock Analysis
When running Apex Biotechnology's price analysis, check to measure Apex Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apex Biotechnology is operating at the current time. Most of Apex Biotechnology's value examination focuses on studying past and present price action to predict the probability of Apex Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apex Biotechnology's price. Additionally, you may evaluate how the addition of Apex Biotechnology to your portfolios can decrease your overall portfolio volatility.